Search

Heron Therapeutics Inc

Lezárt

SzektorEgészségügy

0.26 -16.13

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

0.31

Maximum

0.31

Fő mutatók

By Trading Economics

Bevétel

2.6M

-5.5M

Értékesítés

3M

38M

Egy részvényre jutó nyereség

-0.03

Profit margin

-14.573

Munkavállalók

128

EBITDA

2.1M

-5.5M

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 3.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

-37M

60M

Előző nyitás

16.39

Előző zárás

0.26

Hangulat hírek alapján

By Acuity

71%

29%

298 / 339 Rangsor szerint Healthcare

Heron Therapeutics Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. szept. 20. 04:01 UTC

News

Ethereum is declining, reversing four sessions of gains, with a cumulative return of -2.04% since Saturday amid ongoing geopolitical instability affecting markets.

2026. szept. 20. 04:01 UTC

News

Ethereum is declining, reversing four sessions of gains, amid ongoing geopolitical instability related to the Middle East conflict affecting energy prices and markets.

2026. szept. 20. 02:51 UTC

News

Bitcoin is modestly lower, continuing a trend since Saturday, as the People's Bank of China maintains its one-year Loan Prime Rate at 3.00%.

2026. szept. 20. 02:51 UTC

News

Bitcoin is modestly lower, continuing a trend since Saturday's close, as the People's Bank of China maintains its one-year Loan Prime Rate at 3.00%.

2026. szept. 19. 00:06 UTC

News

Hf Foods Group Inc. has terminated its $100 million equity offering program, with the stock declining in after-market trading following this decision.

2026. szept. 19. 00:02 UTC

News

Block Inc is facilitating Ideal Nutrition's expansion to at least 20 U.S. locations, contributing to a modest increase in its stock during after-market hours.

2026. szept. 19. 00:02 UTC

News
Social Media

MongoDB reported after-market earnings of $771.77 million and EPS of $1.90, exceeding estimates, with stock trading higher in line with market trends.

2026. szept. 19. 00:02 UTC

News
Social Media

Accenture PLC and Anthropic announced a partnership to invest $1 billion each in AI safety, driving a significant increase in Accenture's stock price in after-hours trading.

2026. szept. 19. 00:02 UTC

News

Shares lower in after-market as DOJ reviews antitrust lawsuit.

2026. szept. 19. 00:02 UTC

News
Correlated Moves

Corning Inc's stock is modestly lower in after-market trading, potentially influenced by ASML Holding, despite four consecutive higher daily closes leading into this session.

2026. szept. 19. 00:02 UTC

News

Kimberly-Clark Corp is higher in after-market trading following plans to divest assets related to its $40 billion Kenvue acquisition to address EU antitrust concerns.

2026. szept. 19. 00:01 UTC

News

S&P Global Inc is experiencing modest gains in after-market trading, recovering from an early dip while remaining below its 20-day moving average.

2026. szept. 19. 00:01 UTC

News

RTX Corp is seeing a modest decline in after-market trading, continuing a downward trend since Friday's close and remaining below its 20-day moving average.

2026. szept. 19. 00:01 UTC

News

Union Pacific Corp shares are trading lower in after-market hours, despite UBS upgrading its rating to Buy and raising the price target to $339.

2026. szept. 18. 23:41 UTC

News

Iovance Biotherapeutics granted inducement stock options for 179.75k shares to new employees, contributing to a modest decline in after-market hours.

2026. szept. 18. 23:31 UTC

News

BlackRock Inc. shares are modestly lower in after-market trading amid heightened legal concerns as the DOJ considers intervention in an antitrust lawsuit against the company.

2026. szept. 18. 23:26 UTC

News

State Street Corp declines in after-market trading as the U.S. Department of Justice considers intervention in a state antitrust lawsuit regarding energy price inflation.

2026. szept. 18. 23:16 UTC

News

Union Pacific Corp's stock is trading higher in after-market hours following UBS's upgrade to Buy and a price target increase to $339, citing expected cargo growth.

2026. szept. 18. 23:11 UTC

News

AutoNation Inc has been downgraded from Buy to Hold amid industry challenges, yet the stock is rising in after-market trading as the broader market advances.

2026. szept. 18. 23:11 UTC

News

Leidos Holdings Inc. has secured an $85 million contract from the U.S. Department of War for aerospace systems design, with shares rising in after-market trading.

2026. szept. 18. 23:06 UTC

News

AbbVie Inc. is experiencing a slight decline in after-market trading, positioned near the lower end of its recent trading range despite promising myeloma study results.

2026. szept. 18. 23:06 UTC

News

Boeing is in talks with NASA to expand its Starliner program, potentially adding ten or more flights, as the stock moves higher in after-hours trading.

2026. szept. 18. 23:06 UTC

News

Chevron Corp has declined in after-market trading, despite Goldman Sachs raising its price target to $240 and Piper Sandler setting an even higher target of $243.

2026. szept. 18. 23:06 UTC

News

Okta Inc appointed Helen Riley to its board, enhancing leadership as shares rise in after-market trading, aligning with a broader market advance.

2026. szept. 18. 23:06 UTC

News
Social Media

Nike shares are advancing in after-market hours despite recent challenges, including a significant decline and hitting a 12-year low.

2026. szept. 18. 23:06 UTC

News

General Motors Co is advancing in after-market trading following its decision to reinstate Apple’s CarPlay and Android Auto in its vehicles.

2026. szept. 18. 23:06 UTC

News

Medtronic PLC raised its fiscal 2027 profit forecast and reported first-quarter revenue of $9.756 billion, exceeding expectations, in after-market trading.

2026. szept. 18. 23:06 UTC

News

RTX Corp's backlog hit a record $289 billion, with the stock advancing in after-market trading, despite remaining below its 20-day moving average.

2026. szept. 18. 23:06 UTC

News

Celsius Holdings Inc shares are higher in after-market trading, continuing a positive trend despite ongoing legal scrutiny over its Alani Nu product line.

2026. szept. 18. 23:01 UTC

News
Social Media

Northrop Grumman targets $10 billion in annual international sales by 2031, while shares trade lower in after-market hours.

Társak összehasonlítása

Árváltozás

Heron Therapeutics Inc Előrejelzés

Értékelési konszenzus

By TipRanks

Semleges

2 ratings

0

Vétel

2

Tartás

0

Eladás

Hangulat

By Acuity

298 / 339 Rangsor szerint Egészségügy

Hangulat hírek alapján

Bearish bizonyíték

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag alatti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.